Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | THRA | P10827 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638724 | 0.98 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL1613763 | 0.95 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL30567324 | 0.95 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL6627142 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL6627140 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL9797400 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL5418295 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL2357753 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL12308333 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ALMNATHRA | |
| SCHEMBL3066269 | 0.81 | ALDH1A1 (0.78) | ALDH1A1MEN1KMT2ALMNATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| US-6407115-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION, WATER SOLUBILITY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-5834476-A | DERIVATIVE OF CAMPTOTHECIN, ANTITUMOR AGENT, ANTICARCINOGENIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5770605-A | Method for treating leukemia with a hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5658920-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0495432-B1 | Hexa-cyclic compound | DAIICHI SEIYAKU CO (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0495432-A1 | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3682/4885MEN1 4422/4885KMT2A 3421/4885 |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | ALDH1A1 411/4885MEN1 2195/4885KMT2A 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.